Evidence map›Paper›PMID 40074915›Full record

ReviewMedical oncology (Northwood, London, England)2025

Fisetin as a chemoprotective and chemotherapeutic agent: mechanistic insights and future directions in cancer therapy.

Rabab Fatima, Priyal Soni, Mousmee Sharma, Parteek Prasher, Rajesh Kaverikana, Shivaprasad Shetty Mangalpady, Javad Sharifi-Rad, Daniela Calina

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Unleashing endogenous regeneration by senolytics.Journal of translational medicine · 2025
    Review
  4. Functional Features of Senescent Cells and Implications for Therapy.International journal of molecular sciences · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rabab Fatima *Department of Chemistry, UPES, Dehradun, 248007, India.
Priyal Soni *Amity Institute of Pharmacy, Amity University, Lucknow, 226010, India.
Mousmee SharmaDepartment of Chemistry, Uttaranchal University, Dehradun, 248007, India.
Parteek PrasherDepartment of Chemistry, UPES, Dehradun, 248007, India.
Rajesh KaverikanaDepartment of Pharmacology, Nitte (Deemed to Be University), NGSM Institute of Pharmaceuticals, Mangaluru, India.
Shivaprasad Shetty MangalpadyDepartment of Chemistry, Nitte (Deemed to Be University), NMAM Institute of Technology, Nitte, Karkala, India.
Javad Sharifi-RadUniversidad Espíritu Santo, Samborondón, Ecuador. javad.sharifirad@gmail.com.
Daniela CalinaDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania. calinadaniela@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a leading cause of mortality globally, characterized by the uncontrolled proliferation of abnormal cells, invasion of healthy tissues, and potential metastasis. Natural compounds have become a focus in cancer research due to their potential therapeutic roles. Among these, fisetin, a dietary flavonoid, demonstrates notable anti-cancer properties through various molecular mechanisms. This review evaluates the chemoprotective and chemotherapeutic potential of fisetin, focusing on its mechanisms of action against cancer and its capacity to enhance cancer treatment. A systematic literature search was conducted across PubMed, Web of Science, and Scopus databases using keywords related to fisetin and cancer. The review synthesizes findings from in vitro and in vivo studies examining fisetin's effects on signaling pathways, apoptosis induction, oxidative stress modulation, and synergistic potential with chemotherapeutic agents. Fisetin has shown the ability to suppress tumor growth and metastasis by modulating critical signaling pathways, including PI3K/Akt/mTOR, NF-κB, and MAPK. It induces apoptosis in cancer cells through mitochondrial and endoplasmic reticulum stress responses and demonstrates antioxidative properties by reducing reactive oxygen species. Additionally, fisetin enhances the efficacy of conventional chemotherapies, indicating its role as a potential adjuvant in cancer treatment. Fisetin presents a promising natural compound with diverse anti-cancer effects, impacting cell cycle arrest, apoptosis, and oxidative stress pathways. Further clinical studies are warranted to fully elucidate its therapeutic potential and to optimize its delivery for improved bioavailability in cancer patients.

Indexed as

Antineoplastic AgentsFlavonoidsNeoplasmsAnimalsApoptosisFlavonolsHumansOxidative StressSignal TransductionAntineoplastic AgentsfisetinFlavonoidsFlavonolsAnti-cancerApoptosisBiological functionsCancerFisetinSignaling pathway

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.